Trial Profile
A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Apr 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jun 2011 Planned End Date changed from 1 Aug 2010 to 1 May 2013 as reported by ClinicalTrials.gov.